Kazia plans to outline a regulatory and clinical path forward for paxalisib by January 2025. Get Real-Time News and Alerts for Your Portfolio Kazia Therapeutics Limited KZIA stock is trading lower ...
SYDNEY, Jan. 14, 2025 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA) ("Kazia" or the "Company"), an oncology-focused drug development company, today announced that it has closed its ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback